R-006
Risperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C23H27FN4O2
Numéro CAS:
Poids moléculaire :
410.48
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
certified reference material
Forme
liquid
Caractéristiques
Snap-N-Spike®/Snap-N-Shoot®
Conditionnement
ampule of 1 mL
Fabricant/nom de marque
Cerilliant®
Concentration
1.0 mg/mL in methanol
Technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Application(s)
clinical testing
Format
single component solution
Température de stockage
−20°C
Chaîne SMILES
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
InChI
1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
Clé InChI
RAPZEAPATHNIPO-UHFFFAOYSA-N
Informations sur le gène
human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)
Description générale
Risperidone, marketed as Risperdal®, Ridal, or Riscalin, is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and irritability in autistic children. This new Certified Snap-N-Spike® Solution is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, or urine drug testing.
Application
- Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).
- UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).
- Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).
- Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).
- Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).
Informations légales
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organes cibles
Eyes,Central nervous system
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
49.5 °F - closed cup
Point d'éclair (°C)
9.7 °C - closed cup
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Zhiyun Wei et al.
Journal of clinical psychopharmacology, 33(2), 221-225 (2013-02-21)
Histamine interacts with histamine H4 receptor (HRH4) to impact antipsychotic response. Pharmacogenetic information about this receptor could therefore be useful in developing individualized therapy. The aim of this investigation was to clarify whether polymorphisms at human HRH4 gene alter risperidone
Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
Cécile Danel et al.
Carbohydrate polymers, 92(2), 2282-2292 (2013-02-13)
The interactions between nine drugs (baclofen, bupivacaine, chlorpheniramine, ketoconazole, paliperidone, promethazine, propranolol, risperidone and verapamil) and six cyclodextrins (α-CD, β-CD, γ-CD, HP-β-CD, HP-γ-CD and Me-β-CD) or six polymers of cyclodextrins (polyα-CD, polyβ-CD, polyγ-CD, polyHP-β-CD, polyHP-γ-CD and polyMe-β-CD) were studied by
Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
W Victor R Vieweg et al.
Psychopharmacology, 228(4), 515-524 (2013-07-03)
A recent publication asserted that even low-dose risperidone may induce corrected QT (QTc) interval prolongation up to 500 ms without drug-induced IKr blockade. We seek to better understand the complexity of any link between risperidone-induced/associated QTc interval prolongation and torsade de
Andrea Fagiolini et al.
Expert opinion on pharmacotherapy, 11(10), 1727-1740 (2010-05-22)
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique